Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 19/20 | 0.60 |
| ▸ | PLA2G1B | P04054 | 5/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 3/20 | 0.56 |
| ▸ | PLA2G2E | Q9NZK7 | 3/20 | 0.56 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.56 |
| ▸ | PLA2G2F | Q9BZM2 | 2/20 | 0.54 |
| ▸ | PLA2G2D | Q9UNK4 | 2/20 | 0.54 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.54 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.54 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.54 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5512783 | 0.94 | PLA2G2A (0.59) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL29862343 | 0.94 | PLA2G2A (0.58) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL817430 | 0.94 | PLA2G2A (0.58) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5511347 | 0.93 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5512322 | 0.93 | PLA2G2A (0.58) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5864560 | 0.93 | PLA2G2A (0.57) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5507833 | 0.93 | PLA2G2A (0.60) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5511339 | 0.93 | PLA2G2A (0.61) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5513987 | 0.93 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 | |
| SCHEMBL5514402 | 0.92 | PLA2G2A (0.52) | PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | claimed |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | KINNICK MICHAEL DEAN (US) | 2005-02-03 | — | — | US | claimed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666898-B2 | Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors | ILYPSA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | ILYPSA, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | ILYPSA, INC. | 2008-01-24 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | ILYPSA, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160909-B2 | Cyclopenta[b]indole derivatives as sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | KINNICK MICHAEL DEAN (US) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135385-A1 | Methyl indoxam; obesity; dietectics; antidiabetic agents; insulin resistance; non-insulin dependent diabetes; glucose intolerance; hypercholesterolemia; hypertriglyceridemia; anticholesterol agents; metabolic disorders; foods;bioavailability; side effect reduction | GPR119, INMT, PNLIP | PLA2G2A 246/4885PLA2G1B 42/4885PLA2G10 197/4885 |
| US-20050026988-A1 | Cyclopenta'b! indole derivatives as spla inhibitors | PTGIS, PLA2G4A, PLA2G4B | PLA2G2A 28/4885PLA2G1B 12/4885PLA2G10 38/4885 |
| US-20080021049-A1 | Treatment Of Diet-Related Conditions Using Phospholipase-A2 Inhibitors Comprising Indoles And Related Compounds | PLA2G12A, PLA2G4A, PLA2G2E | PLA2G2A 13/4885PLA2G1B 5/4885PLA2G10 14/4885 |
| US-20080051447-A1 | Treatment Of Hypercholesterolemia, Hypertriglyceridemia And Cardiovascular-Related Conditions Using Phospholipase-A2 Inhibitors | PNLIP, PLA2G1B, PLA2G4A | PLA2G2A 4/4885PLA2G1B 2/4885PLA2G10 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.